Image-guided surgery and light therapy for colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a special dye that helps surgeons see tumors more clearly during surgery, followed by a light therapy to destroy any remaining cancer cells. It is for people with advanced or returning colorectal cancer who are already scheduled for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or returning colorectal cancer and are planning to have surgery.
- You are able to have a CT scan and MRI.
- You are willing to use birth control if there is any chance of pregnancy.
- You do not have porphyria or a known allergy to porphyrin compounds.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation therapy, an immune-boosting drug, and two chemotherapy drugs for colorectal cancer that has spread or come back after two rounds of prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial compares two surgical techniques for removing malignant brain tumors: one using a special dye (5-ALA) that makes tumor cells glow under a blue light, versus the standard white light surgery. The goal is to see if the dye-guided approach helps surgeons remove more of the tumor safely.
This trial looks at whether a special camera/navigation system during minimally invasive (“laparoscopic”) surgery can help treat rectal and sigmoid colon cancer. It is mainly for people who are planned for surgery soon and whose cancer stage and scans fit specific criteria.
This trial tests a combination of oral chemotherapy, targeted therapy, and immunotherapy, with or without radiation, for people with advanced colorectal cancer that hasn't responded to at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a combination of radiation therapy, an immunotherapy drug (QL1706), and two targeted drugs (TAS-102 and bevacizumab) for people with advanced colorectal cancer that has spread and is not removable by surgery. It aims to see if this combination can help shrink tumors or slow cancer growth.
This Phase 1/2 trial tests LYL273, a new targeted treatment, for people with metastatic colorectal (colon) cancer that has returned or not responded to standard chemo. It’s designed to see how well the drug can control the cancer and what side effects it causes.
Hear when a new Locally Advanced Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.